Type II pneumocytes in the evaluation of drug antimycobacterial activity

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 2, 2003, Pages 127-139

  Tomioka, Haruaki ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Atypical mycobacterial infection; Clarithromycin; Levofloxacin; Macrophages; Mycobacterium avium complex; Mycobacterium tuberculosis; Rifalazil; Tuberculosis; Type II alveolar epithelial cells

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 CYCLOPROPYL 7 FLUORO 9 METHYL 8 (OCTAHYDROPYRROLO[3,4 B]PYRIDIN 6 YL) 4 OXO 3 QUINOLIZINECARBOXYLIC ACID; 1,5 BIS(4 CHLOROPHENYL) 2 METHYL 3 (4 METHYL 1 PIPERAZINYLMETHYL)PYRROLE; 2 PYRIDONE DERIVATIVE; 5 AMINO 7 (7 AMINO 5 AZASPIRO[2.4]HEPT 5 YL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; 5 NITROIMIDAZOLE DERIVATIVE; ANTIMYCOBACTERIAL AGENT; CGI 17341; GARENOXACIN; GATIFLOXACIN; GERMACRANOLIDE DERIVATIVE; GREPAFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MICROSPHERE; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; PNU 100480; PYRAZINAMIDE; PYRAZINOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; SITAFLOXACIN; SPARFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMICROBIAL ACTIVITY; ATYPICAL MYCOBACTERIOSIS; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; GENE SEQUENCE; HOST PARASITE INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS CELL TYPE 2; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; CELLS, CULTURED; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPITHELIAL CELLS; HUMANS; LUNG; MACROPHAGES; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM TUBERCULOSIS; PULMONARY ALVEOLI;

EID: 0037324356     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.2.127     Document Type: Review

References (80)

1. KOCHI A, VARELDZIS B, STYBLO K: Multidrug-resistant tuberculosis and its control. Res. Microbiol. (1993) 144:104-110.
2. RILEY LW: Drug-resistant tuberculosis. Clin. Infect. Dis. (1993) 17(Suppl. 2):S442-S446.
3. HART CA, BEECHING NJ, DUERDEN BI: Tuberculosis into the next century. J. Med. Microbiol. (1996) 44:1-34.
4. INDERLIED CB, KEMPER CA, BERMUDEZ LEM: The Mycobacterium avium complex. Clin. Microbiol. Rev. (1993) 6:266-310.
5. FALKINHAM JO: Epidemiology of infection by nontuberculous mycobacteria. Clin. Microbiol. Rev. (1996) 9:177-215.
6. DAUZENBERG B: Clinical trials in Mycobacterium avium therapy: lessons to take home. Res. Microbiol. (1994) 145:197-206.
7. HEIFETS L: Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob. Agents Chemother. (1996) 40:1759-1767.
8. O'BRIEN RJ, LYLE MA, SNIDER DE: Rifabutin (Ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev. Infect. Dis. (1987) 9:519-530.
9. GRASSI C, PEONA V: Use of rifabutin in the treatment of pulmonary tuberculosis. Clin. Infect. Dis. (1996) 22(Suppl. 1):S50-S54.
10. TOMIOKA H: Prospects for development of new antimycobacterial drugs. J. Infect. Chemother. (2000) 6:8-20.
11. SAITO H, TOMIOKA H, SATO K et al.: In vitro antimycobacterial activity of newly synthesized benzoxazinorifamycins. Antimicrob. Agents Chemother. (1991) 35:542-547.
12. INDERLIED CB, BARBARA-BURNHAM L, WU M et al.: Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. Antimicrob. Agents Chemother. (1994) 38:1838-1843.
13. TOMIOKA H: Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648. Arch. Immunol. Ther. Exp. (2000) 48:183-188.
14. TOMIOKA H, SAITO H, SATO K et al.: Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob. Agents Chemother. (1992)36:387-393.
15. BERMUDEZ LE, KOLONOSKI P, YOUNG LS et al.: Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrob. Agents Chemother. (1994) 38:1844-1848.
16. LEYSEN DC, HAEMERS A, PATTYN SR: Mycobacteria and the new quinolones. Antimicrob. Agents. Chemother. (1989) 33:1-5.
17. YEW WW, CHAU CH: New antimycobacterial agents. Monaldi. Arch. Chest Dis.(1996) 51:394-404.
18. ALANGADEN GJ, LERNER SA: The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. (1997) 25:1213-1221.
19. GRASSI C: New drugs for tuberculosis. Expert Opin. Investig. Drugs. (1997) 6:1211-1226.
20. BERNING SE: The role of fluoroquinolones in tuberculosis today. Drugs (2001) 61:9-18.
21. KUNIN CM: Antimicrobial activity of rifabutin. Clin. Infect. Dis. (1996) 22(Suppl. 1):S3-S14.
22. HIRATA T, SAITO H, TOMIOKA H et al.: In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1995) 39:2295-2303.
23. HOFFNER SE, GEZELIUS L, OLSSON-LILJEQUIST B: In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J. Antimicrob. Chemother. (1997) 40:885-888.
24. GILLESPIE SH, KENNEDY N: Fluoroquinolones: a new treatment for tuberculosis? Int. J. Tuberc. Lung Dis. (1998) 2:265-271.
25. JACOBS MR: Activity of quinolones against mycobacteria. Drugs (1999) 58(Suppl 2):19-22.
26. GRIMALDO ER, TUPASI TE, RIVERA AB et al.: Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. (2001) 5:546-550.
27. TOMIOKA H, SATO K, AKAKI T et al.: Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob. Agents Chemother. (1999) 43:3001-3004.
28. ALVIREZ-FREITES EJ, CARTER JL, CYNAMON MH: In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (2002) 46:1022-1025.
29. SAITO H, TOMIOKA H, SATO K et al.: In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob. Agents Chemother. (1994) 38:2877-2882.
30. SAITO H, TOMIOKA H, SATO K et al.: In vitro and in vivo activities of clarithromycin against the Mycobacterium avium complex. Int. J. Antimicrob. Agents (1994) 4:175-181.
31. FATTORINI L, LI B, PIERSIMONI C, TORTOLI E et al.: In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. Antimicrob. Agents Chemother. (1995) 39:680-685.
32. HEIFETS L: Clarithromycin against Mycobacterium avium complex infection. Tuberc. Lung Dis. (1996) 77:19-26.
33. BLANC DC, NUNN P: Incentives and disincentives for new anti-tuberculosis drug development. Situational analysis. World Health Organization (1999).
34. TOMIOKA H: Prospects for development of new antituberculous drugs. Kekkaku (2002) 77:573-584.
35. CYNAMON MH, KLEMENS SP, SHARPE CA et al.: Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicob. Agents Chemother (1999) 43:1189-1191.
36. ASHTEKAR DP, COSTA-PERIRA R, NAGRAJAN K et al.: In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1993) 37:183-186.
37. YAMAMOTO S, TOIDA I, WATANABE N et al.: In vitro antimycobacterial activities of pyrazinamide analogs. Antimicrob. Agents Chemother. (1995) 39:2088-2091.
38. OLEKSIJEW A, MEULBROOK J, EWING P et al.: In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. (1998) 42:2674-2677.
39. DEIDDA D, LAMPIS G, FIORAVANTI R et al.: Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. (1998) 42:3035-3037.
40. SHOEN CM, CHOROMANSKA O, REYNOLDS RC et al.: In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex. Antimicrob. Agents Chemother. (1998) 42:3315-3316.
41. REDDY VM, O'SULLIVAN JF, GANGADHARAM PRJ: Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. (1999) 43:615-623.
42. STOVER CK, WARRENER P, VANDEVANTER DR et al.: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature (2000) 405:962-966.
43. CYNAMON MH, CARTER JL, SHOEN CM: Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. Antimicrob. Agents Chemother. (2000) 44:2895-2896.
44. BERMUDEZ LE, INDERLIED CB, KOLONOSKI P et al.: Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment. Antimicrob. Agents Chemother. (2001) 45:2210-2214.
45. PARRISH NM, HOUSTON T, JONES PB et al.: In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Antimicrob. Agents Chemother. (2001) 45:1143-1150.
46. WALLACE RJ Jr, BROWN-ELLIOTT BA, CRIST CJ et al.: Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. (2002) 46:3164-3167.
47. COLE ST, BROSCH R, PARKHILL J et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 393:537-544.
48. GLICKMAN MS, JACOBS WR Jr: Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell (2001) 104:477-485.
49. MA Y, STERN RJ, SCHERMAN MS et al.: Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzyme and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP rhamnose. Antimicrob. Agents Chemother. (2001) 45:1407-1416.
50. HARTH G, ZAMECNIK PC, TANG JY et al.: Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication. Proc. Natl. Acad. Sci. USA (2000) 97:418-423.
51. KLEMENS SP, CYNAMON MH, SWENSON CE et al.: Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. (1990) 34:967-970.
52. TOMIOKA H, SAITO H, SATO K et al.: Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am. Rev. Respir. Dis. (1991) 144:575-579.
53. BERMUDEZ LE: Use of liposome preparation to treat mycobacterial infections. Immunobiol. (1994) 191:578-583.
54. GANGADHARAM PR, ASHTEKAR DR, FLASHER DL et al.: Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes. Antimicrob. Agents Chemother. (1995) 39:725-730.
55. KANSAL RG, GOMEZ-FLORES R, SINHA I et al.: Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. Antimicrob. Agents Chemother. (1997) 41:17-23.
56. BARROW WW: Treatment of mycobacterial infections. Rev. Sci. Tech. (2001) 20:55-70.
57. DUTT M, KHULLER GK: Therapeutic efficacy of poly (DL-lactide-co-glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. (2001) 45:363-366.
58. SCHRAUFNAGEL DE: Tuberculosis treatment for the beginning of the next century. Int. J. Tuberc. Lung Dis. (1999) 3:651-662.
59. TOMIOKA H, SATO K, MAW WW et al.: The role of tumor necrosis factor, interferon-γ, transforming growth factor-β, and nitric oxide in the expression of immunosuppressive functions of splenic macrophages induced by Mycobacterium avium complex infection. J. Leukoc. Biol. (1995) 58:704-712.
60. COOPER AM, FLYNN JL: The protective immune response to Mycobacterium tuberculosis. Curr. Opin. Immunol. (1995) 7:512-516.
61. VANHAM G, TOSSI Z, ELLNER JJ et al.: Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. Tuberc. Lung. Dis. (1997) 78:145-158.
62. BURMAN WJ: The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review. Am. J. Med. Sci. (1997) 313:355-363.
63. SATO K, AKAKI T, TOMIOKA H: Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. J. Antimicrob.. Chemother. (1998) 41:77-83.
64. BERMUDEZ LE, GOODMAN J: Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect. Immun. (1996) 64:1400-1406.
65. ZHANG M, KIM KJ, IYER D et al.: Effects of Mycobacterium tuberculosis on the bioelectric properties of the alveolar epithelium. Infect. Immun. (1997) 65:692-698.
66. SATO K, TOMIOKA H: Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. J. Antimicrob. Chemother. (1999) 43:351-357.
67. SATO K, TOMIOKA H, SHIMIZU T et al.: Type II alveolar cells play roles in macrophage-mediated host innate resistance to pulmonary mycobacterial infections by producing proinflammatory cytokines. J. Infect. Dis. (2002) 185:1139-1147.
68. MEHTA PK, KING CH, WHITE EH et al.: Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication. Infect. Immun. (1996) 64:2673-2679.
69. SATO K, TOMIOKA H, AKAKI T et al.: Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. Int. J. Antimicrob. Agents (2000) 16:25-29.
70. CHAN J, KAUFMANN SHE. Immune mechanisms of protection. In: Tuberculosis. Pathogenesis, Protection, and Control. Bloom BR (Ed.) ASM Press, Washington DC, USA (1994):389-415.
71. AKAKI T, SATO K, TOMIOKA H et al.: Effector molecules in expression of the antimicrobial activity of macrophages against Mycobacterium avium complex: roles of reactive nitrogen intermediates, reactive oxygen intermediates, and free fatty acids. J. Leukoc. Biol. (1997) 62:795-804.
72. AKAKI T, TOMIOKA H, SHIMIZU T et al.: Comparative roles of free fatty acids with reactive nitrogen intermediates and reactive oxygen intermediates in expression of the anti-microbial activity of macrophages against Mycobacterium tuberculosis. Clin. Exp. Immunol. (2000) 121:302-310.
73. FREHEL C, OFFREDO C, DE CHASTELLIER C: The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin. Infect. Immun. (1997) 65:2792-2802.
74. BERMUDEZ LE, PARKER A, GOODMAN JR: Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway. Infect. Immun. (1997) 65:1916-1925.
75. MCDONOUGH KA, KRESS Y: Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect. Immun. (1995) 63:4802-4811.
76. TOMIOKA H, SATO K, SANO C et al.: Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. Antimicrob. Agents Chemother. (2002) 46:519-521.
77. PIETERS J: Evasion of host cell defense mechanisms by pathogenic bacteria. Curr. Opin. Immunol. (2001) 13:37-44.
78. FERRARI G, NAITO M, LANGEN H et al.: A coat protein on phagosomes involved in intracellular survival of mycobacteria. Cell (1999) 97:435-447.
79. EHLERS MRW, DAFFE M: Interactions between Mycobacterium tuberculosis and host cells: are mycobacterial sugars the key? Trends Microbiol. (1998) 6:328-335.
80. LI Y, PETROFSKY M, BERMUDEZ LE: Mycobacterium tuberculosis uptake by recipient host macrophages is influenced by environmental conditions in the granuloma of the infectious individual and is associated with impaired production of interleukin-12 and tumor necrosis factor α. Infect. Immun. (2002) 70:6223-6230.